Altus Wealth Group LLC Sells 801 Shares of Johnson & Johnson (NYSE:JNJ)

Altus Wealth Group LLC trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 20.4% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 3,132 shares of the company’s stock after selling 801 shares during the quarter. Altus Wealth Group LLC’s holdings in Johnson & Johnson were worth $491,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Louisiana State Employees Retirement System bought a new stake in Johnson & Johnson during the fourth quarter worth about $22,821,000. WCM Investment Management LLC bought a new stake in Johnson & Johnson during the fourth quarter worth about $248,000. MV Capital Management Inc. grew its stake in Johnson & Johnson by 1.0% during the fourth quarter. MV Capital Management Inc. now owns 17,995 shares of the company’s stock worth $2,821,000 after buying an additional 183 shares during the last quarter. Sprucegrove Investment Management Ltd. grew its stake in Johnson & Johnson by 2.4% during the fourth quarter. Sprucegrove Investment Management Ltd. now owns 54,535 shares of the company’s stock worth $8,548,000 after buying an additional 1,300 shares during the last quarter. Finally, Graypoint LLC lifted its position in shares of Johnson & Johnson by 11.4% during the fourth quarter. Graypoint LLC now owns 23,322 shares of the company’s stock worth $3,655,000 after purchasing an additional 2,391 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of research reports. Royal Bank of Canada reduced their target price on shares of Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating on the stock in a research report on Wednesday. Bank of America reduced their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research report on Wednesday. Raymond James upped their target price on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Morgan Stanley reduced their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research report on Wednesday. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Monday, April 15th. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $175.86.

Insider Transactions at Johnson & Johnson

In other news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the sale, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Johnson & Johnson Trading Up 1.5 %

JNJ opened at $147.93 on Friday. The firm’s fifty day moving average is $156.15 and its two-hundred day moving average is $155.63. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.91 and a current ratio of 1.16. The firm has a market cap of $356.48 billion, a PE ratio of 9.22, a price-to-earnings-growth ratio of 2.39 and a beta of 0.53. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $175.97.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.64 by $0.07. The company had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.43%. The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period last year, the business posted $2.68 earnings per share. Equities research analysts anticipate that Johnson & Johnson will post 10.65 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be given a dividend of $1.24 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date of this dividend is Monday, May 20th. This represents a $4.96 annualized dividend and a dividend yield of 3.35%. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.